Literature DB >> 3439798

Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.

R T Mehta1, R L Hopfer, L A Gunner, R L Juliano, G Lopez-Berestein.   

Abstract

Multilamellar vesicles containing nystatin (NYS) were compared with vesicles containing the free drug for toxicity to erythrocytes and for antifungal activity in vitro. Liposomal nystatin was as active as free NYS was against a wide variety of yeasts and fungi. The antifungal activity against Candida albicans was maintained with different liposome compositions and without sterols. Liposome encapsulation also protected the erythrocytes from the toxicity of free NYS.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3439798      PMCID： PMC175823          DOI： 10.1128/AAC.31.12.1897

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Studies on the biological properties of polyene antibiotics: comparison of other polyenes with filipin in their ability to interact specifically with sterol.

Authors:  A W Norman; R A Demel; B de Kruyff; W S Geurts van Kessel; L L van Deenen
Journal:  Biochim Biophys Acta       Date:  1972-12-01

Review 2.  Chemistry and biology of the polyene macrolide antibiotics.

Authors:  J M Hamilton-Miller
Journal:  Bacteriol Rev       Date:  1973-06

3.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

4.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

5.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

6.  Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis.

Authors:  G Lopez-Berestein; R Mehta; R Hopfer; K Mehta; E M Hersh; R Juliano
Journal:  Cancer Drug Deliv       Date:  1983

7.  The action of pimaricin, etruscomycin and amphotericin B on liposomes with varying sterol content.

Authors:  T Teerlink; B de Kruijff; R A Demel
Journal:  Biochim Biophys Acta       Date:  1980-07

8.  Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections.

Authors:  R T Mehta; R L Hopfer; T McQueen; R L Juliano; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

9.  Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice.

Authors:  G Lopez-Berestein; R L Hopfer; R Mehta; K Mehta; E M Hersh; R L Juliano
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226
  9 in total
  20 in total

1.  Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.

Authors:  K L Oakley; C B Moore; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits.

Authors:  Andreas H Groll; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Raul M Alfaro; Christine King; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 3.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

4.  Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma.

Authors:  K M Wasan; M Ramaswamy; S M Cassidy; M Kazemi; F W Strobel; R L Thies
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 5.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

6.  Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.

Authors:  P Deol; G K Khuller; K Joshi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.

Authors:  A H Groll; V Petraitis; R Petraitiene; A Field-Ridley; M Calendario; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.

Authors:  E M Johnson; J O Ojwang; A Szekely; T L Wallace; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.

Authors:  R T Mehta; A Keyhani; T J McQueen; B Rosenbaum; K V Rolston; J J Tarrand
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.

Authors:  R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.